Genomic origin and intratumor heterogeneity revealed by sequencing on carcinomatous and sarcomatous components of pulmonary sarcomatoid carcinoma

Xuewen Liu,Fang Wang,Chunwei Xu,Xinru Chen,Xue Hou,Qian Li,Pansong Li,Zhi Xie,Yongdong Liu,Lianpeng Chang,Yanfang Guan,Xuchao Zhang,Ling Yang,Hui Wang,Xin Yi,Jianjun Zhang,Xuefeng Xia,Cesar Moran,Likun Chen
DOI: https://doi.org/10.1038/s41388-020-01573-9
IF: 8.756
2020-12-03
Oncogene
Abstract:Pulmonary sarcomatoid carcinoma (PSC) contains carcinomatous component (CaC) and sarcomatous component (SaC). Herein, we explored the genomic origin and intratumor heterogeneity (ITH) of PSC. We collected 31 resected PSC tumors and obtained CaC and SaC by laser capture microdissection for next-generation sequencing. The majority of PSCs (97%) had component-shared alterations. Driver mutations in <i>EGFR</i>, <i>KRAS</i>, <i>MET</i>, <i>PIK3CA</i>, and <i>EML4-ALK</i> fusion were mostly component-shared. Twenty-seven (87%) PSCs had component-private alterations. Compared with pure lung adenocarcinoma (LUAD), adenocarcinoma component of PSC showed lower <i>EGFR</i> incidence. Compared with other typical sarcomas, numerous genes of SaC exhibited significant differences. CaC and SaC had equivalent and proportional tumor mutation burden (TMB), as well as PD-L1 level. Compared with LUAD, SaC had significant higher TMB and more patients with high PD-L1 expression (tumor proportion score ≥50%). PSC with lower proportion of component-shared alterations (trunk-ratio) had a prolonged disease-free survival (DFS), regardless of the influence of clinical factors. We conclude that most PSCs originate from a monoclone accompanied by genomic ITH which is a potential independent prognostic factor, and more proportion of PSCs may be beneficial from immune checkpoint inhibitors.
oncology,genetics & heredity,biochemistry & molecular biology,cell biology
What problem does this paper attempt to address?